查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1576740

額顳葉疾病治療市場：按治療類型、治療階段、給藥方法、最終用戶分類 - 全球預測 2025-2030

Frontotemporal Disorders Treatment Market by Therapy Type (Medication, Occupational Therapy, Physical Therapy), Treatment Stage (Early Stage, Late Stage, Mid Stage), Mode Of Administration, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年額顳葉疾病治療市場價值為3.5467億美元，預計到2024年將達到3.6928億美元，複合年成長率為4.02%，到2030年將達到4.6763億美元。

額顳葉疾病 (FTD) 包括一組影響額顳葉的腦部疾病，導致行為、性格、語言和運動技能進行性惡化。這些疾病的盛行率不斷上升，因此需要治療市場，這凸顯了對改善診斷技術、標靶治療和支持性治療以提高患者生活品質的需求。主要應用包括診斷輔助、藥物介入以及新興基因和細胞療法。最終用途範圍包括專注於治療神經退化性疾病的醫院、專科診所、研究機構和製藥公司。市場成長受到神經影像技術進步、對 FTD病理學的更好理解以及未滿足的醫療需求激增等因素的影響。創新藥物開發存在機會，特別是在 FTD 特異性生技藥品和精準醫學領域。擴大臨床試驗並促進生物技術公司和學術研究機構之間的合作可以進一步增加市場潛力。然而，FDA核准的治療方法數量有限、研發成本高昂以及早期診斷方面的挑戰等挑戰持續阻礙市場加速。北美和歐洲等人口老化地區是特別緊迫的市場，這些地區的醫療基礎設施支持先進的研究和治療。對市場相關人員的建議包括投資人工智慧驅動的診斷工具，並探索個人化醫療方法來解決 FTD 的遺傳變異問題。由於目前的治療選擇有限且監管途徑詳細，早期檢測方法和支持性護理技術的創新將使市場參與企業脫穎而出。我們對跨領域研究的持續關注可以帶來顯著改變緩解疾病治療所需的突破。該市場的性質受到嚴格監管，重點關注臨床療效、安全性和全面的患者照護管理，推動融合神經病學和生物技術的多學科方法。

主要市場統計
基準年[2023] 3.5467億美元
預測年份 [2024] 36928萬美元
預測年份 [2030] 46763萬美元
複合年成長率（%） 4.02%

市場動態：揭示快速發展的額顳葉疾病治療市場的關鍵市場洞察

供需的動態交互作用正在改變額顳葉疾病治療市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 增加醫療支出和政府支持神經系統疾病治療的努力
    • 擴大醫療基礎設施以改善額顳葉疾病的診斷和治療
    • 製藥公司之間的合作研究和聯盟，以促進額顳葉疾病治療方法的研究和開發
  • 市場限制因素
    • 開發額顳葉疾病治療方法的高成本會影響患者的經濟負擔
    • 醫療專業人員對額顳葉疾病早期診斷與治療的認知較低
  • 市場機會
    • 增加政府對額顳葉疾病治療研究的資助和舉措
    • 更多採用個人化醫療和標靶治療（額顳葉疾病治療）
    • 早期發現額顳葉疾病的診斷工具和技術的進展
  • 市場問題
    • 來自學名藥和新興生物技術的競爭加劇
    • 疾病機制的複雜性影響通用治療方法的發展

波特五力：駕馭額顳葉疾病治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解額顳葉疾病治療市場的外在影響

外部宏觀環境因素在塑造額顳葉失調治療市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解額顳葉疾病治療市場的競爭狀況

額顳葉疾病治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣額顳葉疾病治療市場供應商的績效評估

FPNV 定位矩陣是評估額顳葉疾病治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃額顳葉疾病治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，額顳葉疾病治療市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 醫療費用上漲和政府支持神經系統疾病治療的努力
      • 擴大醫療基礎設施，以更好地診斷和治療額顳葉疾病
      • 製藥公司之間的合作與夥伴關係，促進額顳葉疾病治療的研發
    • 抑制因素
      • 開發額顳葉疾病治療方法的高昂費用影響患者的支付能力
      • 醫療保健專業人員對額顳葉疾病早期診斷和治療的認知較低
    • 機會
      • 增加政府對額顳葉疾病治療研究的資助和承諾
      • 擴大採用個人化醫療和標靶治療治療額顳葉疾病
      • 早期識別額顳葉疾病的診斷工具和技術的進展
    • 任務
      • 來自學名藥和新興生物技術的競爭加劇
      • 疾病機制的複雜性影響通用治療方法的發展
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章額顳葉疾病治療市場：依治療類型

  • 介紹
  • 藥物治療
    • 抗憂鬱症
    • 抗精神病藥
    • 情緒穩定劑
  • 職能治療
    • 輔助器具培訓
    • 日常生活技能
  • 物理治療
    • 彈性練習
    • 肌力訓練
  • 語言治療
    • 非語言技巧
    • 語言技巧

第7章額顳葉疾病治療市場：依治療階段

  • 介紹
  • 早期的
    • 預防措施
  • 後期
    • 安寧療護
  • 中場
    • 症狀管理

第8章額顳葉疾病治療市場：依管理法

  • 介紹
  • 注射
    • 肌肉注射
    • 靜脈
  • 鼻內
    • 噴
  • 口服
    • 膠囊
    • 錠劑
  • 經皮的
    • 凝膠
    • 修補

第9章額顳葉疾病治療市場：依最終用戶

  • 介紹
  • 居家醫療
  • 醫院
    • 綜合醫院
    • 專科醫院
  • 長期照護中心
  • 研究所
  • 專科診所

第10章北美和南美的額顳葉疾病治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區額顳葉疾病治療市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的額顳葉疾病治療市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-535C62918B38

The Frontotemporal Disorders Treatment Market was valued at USD 354.67 million in 2023, expected to reach USD 369.28 million in 2024, and is projected to grow at a CAGR of 4.02%, to USD 467.63 million by 2030.

Frontotemporal disorders (FTD) encompass a group of brain disorders affecting the fronto-temporal lobes, leading to progressive deterioration in behavior, personality, language, and motor skills. The treatment market is necessitated by the growing prevalence of these disorders, emphasizing the need for improved diagnostic techniques, targeted therapies, and supportive treatments that can enhance patient quality of life. Applications predominantly include diagnostic aids, pharmaceutical interventions, and emerging gene and cell therapies. The end-use scope covers hospitals, specialty clinics, research institutions, and pharmaceutical companies focusing on neurodegenerative disease treatment. Market growth is influenced by factors such as advancements in neuroimaging technologies, increased understanding of FTD pathophysiology, and a surge in unmet medical needs. Opportunities exist in innovative drug development, particularly in biologics and precision medicine tailored specifically for FTD. Expanding clinical trials and fostering collaborations between biotechnology firms and academic research institutions could further propel market potential. However, challenges prevail in the form of limited FDA-approved treatments, high costs associated with R&D, and challenges in early-stage diagnosis, which continue to impede market acceleration. Regions with aging populations are particularly pressing markets, such as North America and Europe, where healthcare infrastructure supports advanced research and treatment accessibility. Recommendations for market players include investing in AI-driven diagnostic tools and exploring personalized medicine approaches to address genetic variances in FTD. Due to limited current therapeutic options and detailed regulatory pathways, innovation in early detection methodologies and supportive care technologies can differentiate market participants. Continued focus on cross-disciplinary research can yield breakthroughs necessary for dramatic shifts in disease-modifying treatments. The nature of the market is tightly regulated with a focus on clinical efficacy, safety, and comprehensive patient care management, pushing an interdisciplinary approach blending neurology and biotechnology.

KEY MARKET STATISTICS
Base Year [2023] USD 354.67 million
Estimated Year [2024] USD 369.28 million
Forecast Year [2030] USD 467.63 million
CAGR (%) 4.02%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Frontotemporal Disorders Treatment Market

The Frontotemporal Disorders Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising healthcare expenditure and government initiatives to support neurological disorder treatments
    • Expansion of healthcare infrastructure enabling better diagnosis and treatment of frontotemporal disorders
    • Collaborations and partnerships between pharmaceutical companies driving research and development in frontotemporal disorder therapies
  • Market Restraints
    • High cost associated with the development of frontotemporal disorder treatments impacting patient affordability
    • Low awareness among medical professionals about early diagnosis and treatment for frontotemporal disorders
  • Market Opportunities
    • Increased government funding and initiatives for research in frontotemporal disorders treatments
    • Growing adoption of personalized medicine and targeted therapies for frontotemporal disorders treatment
    • Advancements in diagnostic tools and techniques to identify frontotemporal disorders at early stages
  • Market Challenges
    • Increasing competition from generic drugs and emerging biotechnologies
    • Complexity of disease mechanisms affects the development of a one-size-fits-all treatment

Porter's Five Forces: A Strategic Tool for Navigating the Frontotemporal Disorders Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Frontotemporal Disorders Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Frontotemporal Disorders Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Frontotemporal Disorders Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Frontotemporal Disorders Treatment Market

A detailed market share analysis in the Frontotemporal Disorders Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Frontotemporal Disorders Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Frontotemporal Disorders Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Frontotemporal Disorders Treatment Market

A strategic analysis of the Frontotemporal Disorders Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Frontotemporal Disorders Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alector, Inc., Amgen Inc., AstraZeneca plc, Biogen Inc., Denali Therapeutics Inc., Eli Lilly and Company, Genentech, Inc., GlaxoSmithKline plc, Ionis Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Prothena Corporation plc, Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, TauRx Pharmaceuticals Ltd., and Wave Life Sciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Frontotemporal Disorders Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy Type, market is studied across Medication, Occupational Therapy, Physical Therapy, and Speech Therapy. The Medication is further studied across Antidepressants, Antipsychotics, and Mood Stabilizers. The Occupational Therapy is further studied across Assistive Devices Training and Daily Living Skills. The Physical Therapy is further studied across Mobility Exercises and Strength Training. The Speech Therapy is further studied across Nonverbal Techniques and Verbal Techniques.
  • Based on Treatment Stage, market is studied across Early Stage, Late Stage, and Mid Stage. The Early Stage is further studied across Preventive Measures. The Late Stage is further studied across Palliative Care. The Mid Stage is further studied across Symptom Management.
  • Based on Mode Of Administration, market is studied across Injectable, Intranasal, Oral, and Transdermal. The Injectable is further studied across Intramuscular and Intravenous. The Intranasal is further studied across Sprays. The Oral is further studied across Capsules and Tablets. The Transdermal is further studied across Gels and Patches.
  • Based on End User, market is studied across Homecare Settings, Hospitals, Long-Term Care Centers, Research Institutes, and Specialty Clinics. The Hospitals is further studied across General Hospitals and Specialized Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising healthcare expenditure and government initiatives to support neurological disorder treatments
      • 5.1.1.2. Expansion of healthcare infrastructure enabling better diagnosis and treatment of frontotemporal disorders
      • 5.1.1.3. Collaborations and partnerships between pharmaceutical companies driving research and development in frontotemporal disorder therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the development of frontotemporal disorder treatments impacting patient affordability
      • 5.1.2.2. Low awareness among medical professionals about early diagnosis and treatment for frontotemporal disorders
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased government funding and initiatives for research in frontotemporal disorders treatments
      • 5.1.3.2. Growing adoption of personalized medicine and targeted therapies for frontotemporal disorders treatment
      • 5.1.3.3. Advancements in diagnostic tools and techniques to identify frontotemporal disorders at early stages
    • 5.1.4. Challenges
      • 5.1.4.1. Increasing competition from generic drugs and emerging biotechnologies
      • 5.1.4.2. Complexity of disease mechanisms affects the development of a one-size-fits-all treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Frontotemporal Disorders Treatment Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Medication
    • 6.2.1. Antidepressants
    • 6.2.2. Antipsychotics
    • 6.2.3. Mood Stabilizers
  • 6.3. Occupational Therapy
    • 6.3.1. Assistive Devices Training
    • 6.3.2. Daily Living Skills
  • 6.4. Physical Therapy
    • 6.4.1. Mobility Exercises
    • 6.4.2. Strength Training
  • 6.5. Speech Therapy
    • 6.5.1. Nonverbal Techniques
    • 6.5.2. Verbal Techniques

7. Frontotemporal Disorders Treatment Market, by Treatment Stage

  • 7.1. Introduction
  • 7.2. Early Stage
    • 7.2.1. Preventive Measures
  • 7.3. Late Stage
    • 7.3.1. Palliative Care
  • 7.4. Mid Stage
    • 7.4.1. Symptom Management

8. Frontotemporal Disorders Treatment Market, by Mode Of Administration

  • 8.1. Introduction
  • 8.2. Injectable
    • 8.2.1. Intramuscular
    • 8.2.2. Intravenous
  • 8.3. Intranasal
    • 8.3.1. Sprays
  • 8.4. Oral
    • 8.4.1. Capsules
    • 8.4.2. Tablets
  • 8.5. Transdermal
    • 8.5.1. Gels
    • 8.5.2. Patches

9. Frontotemporal Disorders Treatment Market, by End User

  • 9.1. Introduction
  • 9.2. Homecare Settings
  • 9.3. Hospitals
    • 9.3.1. General Hospitals
    • 9.3.2. Specialized Hospitals
  • 9.4. Long-Term Care Centers
  • 9.5. Research Institutes
  • 9.6. Specialty Clinics

10. Americas Frontotemporal Disorders Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Frontotemporal Disorders Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Frontotemporal Disorders Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alector, Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca plc
  • 5. Biogen Inc.
  • 6. Denali Therapeutics Inc.
  • 7. Eli Lilly and Company
  • 8. Genentech, Inc.
  • 9. GlaxoSmithKline plc
  • 10. Ionis Pharmaceuticals, Inc.
  • 11. Johnson & Johnson
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Prothena Corporation plc
  • 16. Roche Holding AG
  • 17. Sanofi S.A.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. TauRx Pharmaceuticals Ltd.
  • 20. Wave Life Sciences Ltd.

LIST OF FIGURES

  • FIGURE 1. FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. FRONTOTEMPORAL DISORDERS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. FRONTOTEMPORAL DISORDERS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FRONTOTEMPORAL DISORDERS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. FRONTOTEMPORAL DISORDERS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ASSISTIVE DEVICES TRAINING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY DAILY LIVING SKILLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MOBILITY EXERCISES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY STRENGTH TRAINING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY NONVERBAL TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY VERBAL TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PREVENTIVE MEASURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PALLIATIVE CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPECIALIZED HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LONG-TERM CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 71. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 72. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 76. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 83. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 84. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 85. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 86. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 88. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 89. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 90. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 91. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 96. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 98. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 99. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 100. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 101. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 102. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 104. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 105. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 106. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 107. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 109. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 113. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 115. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 116. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 117. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 118. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 120. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 121. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 122. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 123. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 125. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 131. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 132. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 133. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 134. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 136. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 137. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 138. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 139. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 153. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 154. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 155. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 157. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 175. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 179. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 180. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 181. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 182. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 183. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 184. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 186. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 187. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 188. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 189. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 191. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 196. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 197. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 198. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 199. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 200. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 202. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 203. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 204. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 205. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 207. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 210. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 211. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 212. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 213. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 214. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 215. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 216. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 218. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 219. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 220. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 221. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 223. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 227. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 228. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 229. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 230. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 231. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 232. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 234. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 235. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 236. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 237. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 239. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 241. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 242. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 243. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 244. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 245. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 246. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 247. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 248. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 249. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 250. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 251. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 252. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 253. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 254. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 255. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 257. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 258. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 259. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 260. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 261. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 262. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 263. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 264. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 266. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 267. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 268. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 269. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 270. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 271. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 273. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 274. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 275. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 276. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 277. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 278. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 279. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 280. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 282. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 283. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 284. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 285. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 286. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 287. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 289. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 290. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 291. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 292. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 293. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 294. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 295. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 296. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 297. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 298. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 299. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 300. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRAN